报价延迟最少15分钟:2026/04/15 09:42 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.51 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.53/-0.63
|
|
企业价值
1.28B
|
| 资产负债 |
|
每股账面净值
0.73
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cellactivation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment. |
